Lean oncology: a new model for oncologists

od Montesarchio, Vincenzo, Grimaldi, Antonio Maria, Fox, Bernard A, Rea, Antonio, Marincola, Francesco M, Ascierto, Paolo A
Izdano 2012

Do BRAF inhibitors select for populations with different disease progression kinetics?

od Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Izdano 2013

Serious haematological toxicity during and after ipilimumab treatment: a case series

od Simeone, Ester, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Palla, Marco, Paone, Miriam, Mozzillo, Nicola, Ascierto, Paolo Antonio
Izdano 2014

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

od Stucci, Stefania, Tucci, Marco, Ascierto, Paolo Antonio, Passarelli, Anna, Mariaelena, Capone, Madonna, Gabriele, Ester, Simeone, Grimaldi, Antonio Maria, Silvestris, Franco
izdano v J Transl Med (2015)

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series

od Di Monta, Gianluca, Caracò, Corrado, Marone, Ugo, Grimaldi, Antonio Maria, Anniciello, Anna Maria, Di Marzo, Massimiliano, Simeone, Ester, Mori, Stefano
izdano v BMC Res Notes (2015)

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

od Montella, Maurizio, Gandini, Sara, Rossi, Carlo Riccardo, Testori, Alessandro, Mastrangelo, Giuseppe, Serraino, Diego, Budroni, Mario, Crispo, Anna, Grimaldi, Antonio Maria, Ascierto, Paolo Antonio
Izdano 2014

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report

od Falivene, Sara, Giugliano, Francesca Maria, Grimaldi, Antonio Maria, Di Franco, Rossella, Toledo, Diego, Muto, Matteo, Cammarota, Fabrizio, Borzillo, Valentina, Ascierto, Paolo Antonio, Muto, Paolo
Izdano 2014

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

od Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Vanella, Vito, Palla, Marco, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola, Ascierto, Paolo Antonio
izdano v Oncoimmunology (2017)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

od Grimaldi, Antonio Maria, Simeone, Ester, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
izdano v J Immunother Cancer (2015)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

od Simeone, Ester, Benedetto, Lucia, Gentilcore, Giusy, Capone, Marilena, Caracò, Corrado, Di Monta, Gianluca, Marone, Ugo, Di Cecilia, Marialuisa, Grimaldi, Antonio Maria, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo A
Izdano 2014

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

od Di Monta, Gianluca, Caracò, Corrado, Simeone, Ester, Grimaldi, Antonio Maria, Marone, Ugo, Di Marzo, Massimiliano, Vanella, Vito, Festino, Lucia, Palla, Marco, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo Antonio
izdano v J Transl Med (2017)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

od Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe, Cavalcanti, Ernesta, Caracò, Corrado, Ascierto, Paolo Antonio
izdano v J Immunother Cancer (2018)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

od Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Rinaldi, Giovanni, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
izdano v J Immunother Cancer (2015)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

od Queirolo, Paola, Spagnolo, Francesco, Picasso, Virginia, Spano, Laura, Tanda, Enrica, Fontana, Valeria, Giorello, Laura, Merlo, Domenico Franco, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Del Vecchio, Michele, Bruzzi, Paolo, Ascierto, Paolo Antonio
izdano v Oncotarget (2016)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma

od Scognamiglio, Giosuè, Capone, Mariaelena, Sabbatino, Francesco, Di Mauro, Annabella, Cantile, Monica, Cerrone, Margherita, Madonna, Gabriele, Grimaldi, Antonio Maria, Mallardo, Domenico, Palla, Marco, Sarno, Sabrina, Anniciello, Anna Maria, Di Bonito, Maurizio, Ascierto, Paolo Antonio, Botti, Gerardo
izdano v Cancers (Basel) (2021)

Clinical trials and drug cost savings for Italian health service

od D’Ambrosio, Francesca, De Feo, Gianfranco, Botti, Gerardo, Capasso, Arturo, Pignata, Sandro, Maiolino, Piera, Triassi, Maria, Nardone, Antonio, Perrone, Franco, Piezzo, Michela, Grimaldi, Antonio Maria, Palazzo, Ida, De Stasio, Immacolata, D’Aniello, Roberta, Morabito, Alessandro, Pascarella, Giacomo
izdano v BMC Health Serv Res (2020)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

od Daponte, Antonio, Signoriello, Simona, Maiorino, Luigi, Massidda, Bruno, Simeone, Ester, Grimaldi, Antonio Maria, Caracò, Corrado, Palmieri, Giuseppe, Cossu, Antonio, Botti, Gerardo, Petrillo, Antonella, Lastoria, Secondo, Cavalcanti, Ernesta, Aprea, Pasquale, Mozzillo, Nicola, Gallo, Ciro, Comella, Giuseppe, Ascierto, Paolo Antonio
Izdano 2013

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

od Simeone, Ester, Romano, Maria fiammetta, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Paone, Miriam, Rinaldi, Giovanni, Di monta, Gianluca, Di marzo, Massimiliano, Hauber, Federica, Festino, Lucia, D'Angelillo, Anna, Romano, Simona, Staibano, Stefania, Ilardi, Gennaro, Bisogni, Rita, Mozzillo, Nicola, Ascierto, Paolo Antonio
izdano v J Immunother Cancer (2014)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

od Chiarion Sileni, Vanna, Pigozzo, Jacopo, Ascierto, Paolo Antonio, Grimaldi, Antonio Maria, Maio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, de Rosa, Francesco, Nuzzo, Carmen, Testori, Alessandro, Cocorocchio, Emilia, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Merelli, Barbara, Parmiani, Giorgio, Rinaldi, Gaetana, Aglietta, Massimo, Grosso, Marco, Queirolo, Paola
Izdano 2014

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

od Montesarchio, Vincenzo, Parrella, Roberto, Iommelli, Chiara, Bianco, Antonella, Manzillo, Elio, Fraganza, Fiorentino, Palumbo, Cristiana, Rea, Gaetano, Murino, Patrizia, De Rosa, Rosanna, Atripaldi, Luigi, D’Abbraccio, Maurizio, Curvietto, Marcello, Mallardo, Domenico, Celentano, Egidio, Grimaldi, Antonio Maria, Palla, Marco, Trojaniello, Claudia, Vitale, Maria Grazia, Million-Weaver, Samuel Lewis, Ascierto, Paolo Antonio
izdano v J Immunother Cancer (2020)